RiboQuark Doses First Patient in China siRNA Trial

Published on: November 14, 2017
Author: Amy Liu

Kunshan RiboQuark Pharma has dosed the first person in a China trial of a siRNA ocular neuroprotectant therapy. The therapeutic (QPI-1007) treats a “stroke in the eye,” known more technically as acute non-arteritic ischemic optic neuropathy (NAION). QPI-1007 temporarily inhibits expression of the apoptotic protein, Caspase 2. RiboQuark is a JV formed by two siRNA companies: Ribo Life Science, headquartered in Kunshan, Jiangsu Province, and Quark Pharma, a US-Israeli company.

Source: China Biotoday

Biotechnology China News Pharmaceutical